Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 505

Similar articles for PubMed (Select 15091197)

1.

Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.

Noter SL, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA.

Melanoma Res. 2004 Feb;14(1):67-72.

PMID:
15091197
2.

Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.

Rothbarth J, Pijl ME, Vahrmeijer AL, Hartgrink HH, Tijl FG, Kuppen PJ, Tollenaar RA, van de Velde CJ.

Br J Surg. 2003 Nov;90(11):1391-7.

PMID:
14598420
3.

Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver.

Alexander HR Jr, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T.

Clin Cancer Res. 2003 Dec 15;9(17):6343-9.

4.

A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.

Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC.

Clin Cancer Res. 2000 Aug;6(8):3062-70.

5.

Isolated hepatic perfusion for liver metastases of malignant melanoma.

Rizell M, Mattson J, Cahlin C, Hafström L, Lindner P, Olausson M.

Melanoma Res. 2008 Apr;18(2):120-6. doi: 10.1097/CMR.0b013e3282f8e3c9.

PMID:
18337648
6.

Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.

Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T, Alexander HR Jr.

Ann Surg Oncol. 2010 Jul;17(7):1870-7. doi: 10.1245/s10434-010-0998-z. Epub 2010 Mar 11.

PMID:
20221901
7.

Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.

van Etten B, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C.

Eur J Surg Oncol. 2009 May;35(5):539-45. doi: 10.1016/j.ejso.2008.07.004. Epub 2008 Aug 28.

PMID:
18760560
8.

Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.

Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T.

Ann Surg Oncol. 2005 Feb;12(2):138-44. Epub 2005 Feb 4.

PMID:
15827794
9.

Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.

van Iersel LB, Verlaan MR, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Sparidans RW, Gelderblom H, Kuppen PJ, Tollenaar RA, van de Velde CJ.

Eur J Surg Oncol. 2007 Sep;33(7):874-81. Epub 2007 Apr 2.

PMID:
17400422
10.

Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.

Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T.

Melanoma Res. 2005 Aug;15(4):297-304.

PMID:
16034309
11.

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA.

J Clin Oncol. 1998 Apr;16(4):1479-89.

PMID:
9552055
12.

Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.

van Iersel LB, Hoekman EJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ.

Ann Surg Oncol. 2008 Jul;15(7):1891-8. doi: 10.1245/s10434-008-9881-6. Epub 2008 May 10.

13.
14.

Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.

Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR.

Surgery. 2001 Feb;129(2):176-87.

PMID:
11174711
15.

Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.

Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, Lindnér P.

Ann Surg Oncol. 2014 Feb;21(2):466-72. doi: 10.1245/s10434-013-3304-z. Epub 2013 Oct 19.

PMID:
24141377
16.

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ.

Br J Cancer. 2000 May;82(9):1539-46.

17.

Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment.

Heusner TA, Antoch G, Wittkowski-Sterczewski A, Ladd SC, Forsting M, Verhagen R, Scheulen M.

Rofo. 2011 Dec;183(12):1151-60. doi: 10.1055/s-0031-1281743. Epub 2011 Oct 27.

PMID:
22033849
18.

Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.

van Iersel LB, de Leede EM, Vahrmeijer AL, Tijl FG, den Hartigh J, Kuppen PJ, Hartgrink HH, Gelderblom H, Nortier JW, Tollenaar RA, van de Velde CJ.

Eur J Surg Oncol. 2014 Nov;40(11):1557-63. doi: 10.1016/j.ejso.2014.06.010. Epub 2014 Jul 25.

PMID:
25125340
19.

Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients.

van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ.

Ann Oncol. 2008 Jun;19(6):1127-34. doi: 10.1093/annonc/mdn032. Epub 2008 Feb 27.

20.

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.

Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM.

Ann Surg Oncol. 2005 Aug;12(8):609-15. Epub 2005 Jun 22.

PMID:
15968498
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk